BioCentury
ARTICLE | Company News

Berg, Beth Israel Deaconess, Cancer Research and Biostatistics deal

May 11, 2015 7:00 AM UTC

The partners will identify and develop biomarkers for pancreatic cancer under a five-year deal. Beth Israel and Cancer Research and Biostatistics will design clinical trials and provide patient samples and treatment results to Berg for analysis using its Interrogative Biology platform. The partners will form a joint steering committee upon identification of a lead biomarker. Berg will be responsible for biomarker discovery, development and commercialization. The partners declined to disclose financial terms. ...